Skip to main content
. 2012 Apr 20;7(4):e35559. doi: 10.1371/journal.pone.0035559

Figure 4. Results of the “screen and treat” (population-wide screening) analysis: multivariate sensitivity analysis.

Figure 4

The strategy with maximum net monetary benefit is depicted as a function of the assumed prevalence of AD in the general over-60 population (between 0 and 10%) and specificity of the MRI+CLP diagnostic test between 0.90 and 1, for assumed costs of the CLP contrast agent between 0 and 500€ per injection: (a) Cost of the CLP contrast agent at 50 €/injection. (b) Cost of the CLP contrast agent at 250 €/injection (base-case). (c) Cost of the CLP contrast agent at 500 €/injection.